Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Space Exploration Technologies Corp. (SpaceX) | Equinix | Tempus AI | |
|---|---|---|---|
| Moat rating | narrow The moat is narrow rather than wide. The filing names real entry barriers in launch — capital, technological expertise, licences and established government and commercial relationships — and adds spectrum and orbital resources in connectivity, while warning that the company's "leadership position in various markets, especially in orbital launch services" could attract competition-law scrutiny. The AI segment has barriers too: "Our AI businesses likewise compete in markets characterized by significant barriers to entry." Durability is capped by three-to-five-year satellite lives that force perpetual replacement launches, but the moat is not eroding: subscribers are 12.0M against 6.0M. | wide The FY2025 10-K (filed 2026-02-11) grounds the advantage in an asset that took 27 years to assemble and that a competitor cannot buy: "Over our 27-year history, we have curated a diverse, industry-leading ecosystem of more than 500,000 interconnections", "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", across "280 data centers, in 77 markets in 36 countries", with "99.9999%+ operational uptime" delivered in 2025 and no single customer at 10% of revenue. Because the value of each IBX rises with who else is already inside it, incumbency compounds rather than decays. The counterweight is real and disclosed: Item 1A says "The global multi-tenant data center market is highly fragmented. It is estimated that we are one of more than 2,400 companies that provide these offerings around the world", and warns that competitors "may adopt aggressive pricing policies". That caps the pricing that the moat converts into, not its durability — the fragmentation sits in commodity space-and-power, while the interconnection density the filing describes has no comparable substitute. FY2025 revenue of $9.217B with operating margin recovering to 20.0% from 15.2% in FY2024 is consistent with the incumbency holding. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | cost scale The advantage is cost and scale. The stated model is extreme vertical integration plus reusability driving unit cost down: per NASA, the first Falcon 9 cut launch cost to about $2,700/kg, roughly 85% below the $18,500/kg historical average, and Falcon 9 has "demonstrated the ability to refly a first-stage 34 times" (3/31/26). The filing credits rising cadence, cargo capacity and "declining unit costs—driven by rapid reusability—have generated a compounding competitive advantage". SpaceX also launches its own constellation, and Competition notes "some of these service providers are also launch customers of SpaceX". Spectrum and licence intangibles reinforce the cost advantage. | network effects The 10-K names the mechanism itself, twice and unprompted: "As more customers choose Equinix for high connectivity and performance reliability at the metro edge, it benefits their suppliers and business partners to colocate in the same data centers and connect directly with each other. This adjacency creates a network effect that attracts new customers while continuously enhancing our value proposition to existing customers", and in the Competitive Landscape section, "This ecosystem creates a network effect that improves performance and lowers the cost for our customers". The evidence is the count of participants rather than any patent or unit-cost claim — 500,000+ interconnections, 2,000+ network service providers, a leading share of cloud on-ramps, an Internet Exchange the filing calls "the largest global peering solution". Switching costs are a genuine second layer (fixed-duration contracts billed on space and power, physical cross connects into resident counterparties), but they are what holds a customer already inside the ecosystem; the reason to enter in the first place is who is already there. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | clear leader SpaceX leads clearly in its two established segments but not in its newest. The prospectus calls it "the primary launch provider for the U.S. government" — 11 of 12 NSSL medium and heavy lift missions and all five U.S. crew and cargo ISS missions for NASA in 2025 — and says Starlink is "the sole low-latency network available globally", low-latency self-defined as under 70ms; it flags competition-law scrutiny risk from that leadership. AI is the exception, with OpenAI, Anthropic, Google, Meta and Microsoft named as competitors, some with greater resources, in a segment the filing calls early stage. Cadence slipped: H1 2026 Falcon launches 77 versus 81, mass to orbit 1,041t versus 1,102t. | clear leader Leadership is claimed on interconnection, not on square footage, and the filing's own evidence is about density: "our position is unmatched in the industry" is supported by 2,000+ resident network service providers, "a leading market share of cloud-on ramps", 500,000+ interconnections and an Internet Exchange described as "the largest global peering solution", across 36 countries. The band is read against neutral, ecosystem-dense colocation, where that footprint has no direct analogue. It is deliberately not read against total data centre capacity: the same 10-K puts Equinix among "more than 2,400 companies" in a "highly fragmented" MTDC market, and Item 1A concedes the company must compete for land and power against "new market entrants" drawn in by AI. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | moderate Pricing power is moderate — a deliberate give-back from a cost position rather than weakness. Management states its strategy is "rather than prioritizing increases in ARPU" and expects Starlink ARPU to keep declining as it adds lower-priced plans and adjusts monthly service fees; the Q2 10-Q shows ARPU of $66 versus $85 while Connectivity operating income rose 79.4%. Launch sells on fixed-price contracts, one to five years for Launch Services and up to fourteen for Launch and Development. Concentration is material: about one-fifth of 2025 revenue came from U.S. federal agencies, with all launch contracts firm fixed-price and terminable at the government's convenience without advance notice. | moderate Contract structure supports price: fixed-duration agreements billed on space and power plus per-connection interconnection fees, an installed base too physically entangled to move cheaply, and 99.9999%+ uptime in 2025 as the thing being paid for. FY2025 revenue of $9.217B grew about 5% on FY2024's $8.748B while operating margin recovered to 20.0% from 15.2%, so pricing and cost were at least held. But the filing itself refuses the strong band: competitors "may adopt aggressive pricing policies, especially if they are not highly leveraged or have lower return thresholds than we do. As a result, we may suffer from pricing pressure that would adversely affect our ability to generate revenues", and some rivals bundle communications or cloud services against bare colocation. Power procurement is a further pass-through risk the filing flags. Price is defended, not dictated. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | Two real moats and one expensive bet. Launch and Starlink rest on facts the filing states outright: barriers of capital, technology, licences, spectrum and orbital resources; about 9,600 satellites, roughly 75% of all active maneuverable satellites in orbit; the only globally available low-latency network; a NASA-cited cost per kilogram about 85% below the historical average; a first stage reflown 34 times. Connectivity rivals buy launches from it. What caps it: satellites live three to five years and must be perpetually replaced; H1 2026 Falcon launches and mass to orbit both fell and Falcon 9 flights are expected to decline; about 20% of 2025 revenue is U.S. federal, competitively bid and terminable at will; 86% of Q2 capex ($15.8bn of $18.4bn) went to an AI segment whose cloud revenue sits with few customers on 90-day-terminable contracts. Q2 operating loss $143M; H1 loss $2,086M. | Equinix is a network-neutral, multi-tenant colocation and interconnection REIT: it does not sell compute, it sells the metro-edge real estate where networks, clouds and enterprises physically meet. The FY2025 10-K describes the platform as "280 data centers, in 77 markets in 36 countries" serving "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", carrying "more than 500,000 interconnections" curated over 27 years, with 61% of 2025 revenue recognised outside the U.S. Revenue is structurally recurring — infrastructure offerings are "billed based on the space and power a customer consumes" under fixed-duration contracts generating MRR, interconnection is "billed based on the outbound connections from a customer" — and no customer reached 10% of 2025 revenue. AI enters the story as demand rather than as a product: the filing positions Equinix as the interconnect point for "model providers, data platforms, neoclouds and gateways", and pushes core hyperscale capacity into xScale, which is "developed and operated through our joint venture partnership arrangements". The bear case is in the company's own Item 1A. The MTDC market is "highly fragmented", Equinix being "one of more than 2,400 companies"; competitors "may adopt aggressive pricing policies"; the AI build-out invites "significant investments in the data center industry by both current competitors and new investors", after which "we could lose market share" and must "compete against certain of these competitors to secure the land and power needed for our expansion plans". Product extension has also failed before — the filing notes past offerings "have been or are being discontinued, including the Equinix Metal product". The honest reading: the interconnection ecosystem is close to unreplicable and the moat sits there; the capacity business around it is a capital race Equinix enters with scale but no immunity. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | — | Equinix is the neutral meeting point of the AI and cloud supply chain rather than a link in its manufacturing path: it houses other companies' compute and sells the adjacency between them. The 10-K places it between the network layer (2,000+ service providers), the cloud layer ("a leading market share of cloud-on ramps") and enterprise consumers who "assemble these capabilities into operational stacks", and describes an AI ecosystem "of model providers, data platforms, neoclouds and gateways" curated for enterprise AI demand. Core hyperscale training capacity sits beside that, not inside it, in xScale, built with JV partners so hyperscalers "add to their core hyperscale data center deployments and existing customer access points at Equinix". The revenue is therefore levered to AI's distribution and inference edge more than to training-cluster buildout. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |